FREMANEZUMAB
Information current as at: 1 July 2026
PBAC meeting date: November 2026
Submission Details
- Brand name:
-
- Ajovy®
- Form and strength:
-
- Solution for injection 225 mg in 1.5 mL single dose pre-filled syringe
- Solution for injection 225 mg in 1.5 mL single dose auto-injector
- Submission sponsor:
- TEVA PHARMA AUSTRALIA PTY LTD
- Condition/indication:
(therapeutic use) -
- Treatment-resistant migraine
- Listing requested:
- To request listing of fremanezumab for treatment-resistant migraine to enable 3-monthly dosing in addition to the existing monthly dosing. This item was previously recommended by the PBAC at its March 2022 meeting.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- Change to existing listing (–)
- Comment:
- --
- Other PBAC consideration:
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
2Opportunity for consumer comment:
- Open 22/07/2026 and close 16/09/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1279
Page last updated
23 July 2026
v.9.19